MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases. MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. History The Company was founded in 1992. In 1999, MorphoSys listed on the Frankfurt Stock Exchange under the ticker symbol "MOR". In 2004, MorphoSys and Novartis entered into a strategic partnership for the research and development of biopharmaceuticals, which was expanded in 2007. Additional discovery partnerships included: Bayer (1999), Roche (2000), Centocor (now Janssen Biotech, 2000), Schering AG (2001) and Pfizer (2003). In 2008, the company’s first proprietary antibody MOR103 (now otilimab) entered clinical development. Following the publication of promising results in rheumatoid arthritis, MorphoSys signed a license agreement with GlaxoSmithKline for otilimab. In 2019, GlaxoSmithKline initiated a phase 3 clinical development program with otilimab (now GSK3196165). In 2010, MorphoSys signed a license agreement with Xencor Inc. for MOR208 (now tafasitamab). In July 2017, the first of MorphoSys’ platform drugs received US marketing approval. Guselkumab (brand name Tremfya), which was developed and is being commercialized by Janssen Biotech a subsidiary of Johnson & Johnson, was first approved for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union and Canada. In April 2018, following a US initial public offering in which the company raised $239 million, American depositary shares of MorphoSys began trading on the Nasdaq stock exchange, also under the symbol "MOR." In 2018, the company established a wholly owned US subsidiary, MorphoSys US Inc.. In December 2019, based on positive clinical trial results, the company submitted a Biologics License Application (BLA) to the FDA for tafasitamab in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma. The submission was accepted for filing in February 2020, and a decision on the filing is expected in August 2020. In January 2020, MorphoSys and Incyte Corporation signed a